申请人:MITSUBISHI TANABE PHARMA CORPORATION
公开号:US20140296183A1
公开(公告)日:2014-10-02
A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier.
wherein R is a hydrogen atom or P(═O)(OH)
2
, X is an oxygen atom or a sulfur atom, Y is CH
2
CH
2
or CH═CH, R
1
is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R
2
is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R
3
and R
4
may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.
以下是一种新型胺化合物的化学式(I),它在免疫抑制作用、抗排斥作用等方面具有优异的表现,并显示出缩短心跳等副作用的减少,或其药学上可接受的酸盐、水合物或溶剂化物,以及包含该化合物和药学上可接受的载体的制药组合物。其中,R是氢原子或P(═O)(OH)2,X是氧原子或硫原子,Y是CH2CH2或CH═CH,R1是氰基或具有1至4个碳原子的烷基,并被卤素原子取代,R2是具有1至4个碳原子的烷基,可选择地被羟基或卤素原子取代,R3和R4可能相同也可能不同,每个都是氢原子或具有1至4个碳原子的烷基,n为5-8。